Kisspeptin-10

Kisspeptin-10 is a short, biologically active C-terminal fragment of the kisspeptin peptide family. It has been studied as a KISS1R agonist in reproductive neuroendocrine research.

Yes. It is a peptide fragment whose conserved C-terminal sequence retains activity at KISS1R in experimental settings.

KISS1 is the gene that encodes a precursor processed into kisspeptin peptides. These peptides have been associated with regulation of reproductive neuroendocrine signaling.

KISS1R is a G-protein-coupled receptor activated by kisspeptins and studied as a major regulator of reproductive neuroendocrine pathways.

Yes. GPR54 is the historical name for the receptor now commonly called KISS1R.

Research suggests that its conserved C-terminal region binds and activates KISS1R. The resulting response depends on the cellular and experimental model.

KISS1R activation is generally associated with Gq/11 signaling that may engage phospholipase C, IP3, DAG and intracellular calcium mobilization.

It is principally studied as an upstream signal that may activate hypothalamic GnRH neurons and stimulate GnRH release in experimental settings.

GnRH can signal at pituitary GnRH receptors and influence secretion of luteinizing hormone and follicle-stimulating hormone. The pattern depends on experimental and biological context.

In some human studies, the observed LH response has been more pronounced than the FSH response. This is not universal and does not establish a guaranteed effect.

It is the research axis linking hypothalamic GnRH signaling, pituitary LH and FSH secretion, and gonadal responses.

Yes. It has been investigated in fertility, ovulation, hypogonadotropic hypogonadism and broader reproductive-physiology research. This does not establish therapeutic efficacy.

Yes. Controlled research has examined endocrine responses in male participants, but those findings do not establish safety, efficacy or equivalence for this product.

Yes. Research has examined responses across different hormonal states and cycle phases. Results are context-dependent and do not authorize this product as a medicine.

A direct or guaranteed increase is not established. Any downstream change studied would involve a context-dependent neuroendocrine cascade rather than proven direct stimulation.

It is primarily studied upstream at KISS1R and GnRH neurons, not as a direct gonadal stimulant. Downstream responses vary by model and hormonal context.

No direct, reliable increase in libido has been established. Reproductive-axis research should not be interpreted as proof of a behavioral or therapeutic effect.

No. ELIX LABS does not present Kisspeptin-10 as an aphrodisiac, and it is not intended for human use.

No. ELIX LABS Kisspeptin-10 is an experimental research material, not an approved medicine, and its safety and efficacy are not established.

No. Clinical investigation does not itself confer regulatory approval, and controlled-study results do not automatically validate a separate commercial research product.

They are different-length members of the kisspeptin family that share a KISS1R-active C-terminal region. Their pharmacokinetic properties and experimental contexts are not identical, so they are not interchangeable without specific data.

Kisspeptin-10 is studied upstream of GnRH neurons, while Gonadorelin is synthetic GnRH studied directly at pituitary GnRH receptors. Both may relate to LH and FSH research, but they act at different levels and are not equivalents or substitutes. This is not a usage recommendation.

Kisspeptin-10 is studied through KISS1R, GnRH and reproductive-axis regulation. PT-141, or bremelanotide, is a melanocortin analogue studied in different central neural pathways related to motivation and sexual response. Their structures, receptors and research axes differ; this is not a usage recommendation.

No. Shared receptor activity does not make their lengths, pharmacokinetics or experimental behavior identical. Findings require form-specific evaluation.

Responses may vary according to sex, hormonal state, cycle phase, species, tissue system, exposure pattern and protocol. An acute response does not predict repeated-exposure effects.

Safety, immunogenicity, impurity profiles, biodistribution and repeated-exposure effects remain uncertain. The FDA has identified concerns for compounded Kisspeptin-10 involving potential immunogenicity, peptide-related impurities and limited safety information; this does not establish the quality of a distinct research product.

Follow the batch-specific documentation supplied with the product and validated laboratory handling procedures. No temperature recommendation should replace the instructions provided with the lot.

No. For laboratory research use only. Not for human consumption. It is not intended for human administration.

The product includes access to the four listed research resources and available batch-specific analytical documentation, including the Certificate of Analysis.